awmsg logo



eplerenone (Inspra®)


Reference No. 763

Publication date:
23/01/2013


Appraisal information

eplerenone (Inspra®) 25 mg film-coated tablet
eplerenone (Inspra®) 50 mg film-coated tablet


Company: Pfizer Ltd
BNF category: Cardiovascular system
NMG meeting date: 07/11/2012
AWMSG meeting date: 12/12/2012
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2712
Ministerial ratification: 16/01/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Eplerenone (Inspra®) is recommended as an option for use within NHS Wales in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with New York Heart Association (NYHA) class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF ≤ 30%).
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download